Clinical trials: Systemic AL Amyloidosis
Light Chain Amyloidosis
FKC288 for Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
This study is a single-center exploratory clinical trial. It is estimated that 6-12 subjects will be enrolled. The "BOIN" dose escalation design is adopted.
- Trial name
- NCT05978661
- Testing
- FKC288
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Nanjing University School of Medicine
Primary Systemic Amyloidosis, Light Chain Deposition Disease
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
RATIONALE: Giving bortezomib together with melphalan and dexamethasone may be an effective treatment for primary amyloidosis and light chain deposition disease.
- Trial name
- NCT00520767
- Testing
- bortezomib, dexamethasone, melphalan
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Systemic Amyloidosis
124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis
This is a single-center, exploratory, Phase 1 Positron Emission Tomography/x-ray Computed Tomography (PET/CT) imaging study to detect amyloidosis that will enroll patients with a confirmed diagnosis of systemic amyloidosis.
- Trial name
- NCT03678259
- Testing
- 124I-p5+14 Injection
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Tennessee Graduate School of Medicine
Chronic Myeloproliferative Disorders, Leukemia
EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer
RATIONALE: EMD 121974 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of EMD 121974 in treating patients who have locally advanced or metastatic cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004258
- Testing
- cilengitide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Indiana University